Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232726 · ClinicalTrials.gov registry record · Phase 2
Clinical Study of Previously Untreated Patients With Malignant Melanoma
A Phase 2 study, sponsored by Clavis Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00232726 is a Phase 2 study that has completed, run by Clavis Pharma. The registered enrollment target is 42 participants.
The verdict
NCT00232726, a Phase 2 study, has completed, sponsored by Clavis Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.
Interventions
- DRUG CP-4055 (ELACYT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232726
The ClinicalTrials.gov registry entry for NCT00232726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clavis Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-4055 (ELACYT) is the first listed.
NCT00232726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232726 about?
NCT00232726 is a clinical study titled "Clinical Study of Previously Untreated Patients With Malignant Melanoma". Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.
What is the current status of trial NCT00232726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2005-09. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00232726?
The interventions under investigation include: CP-4055 (ELACYT) (DRUG).
Who is sponsoring clinical trial NCT00232726?
This trial is sponsored by Clavis Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.